AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35321558 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline RAS inhibitor or non-inhibitor treatments
Number of subjects: 203
Study 34460179 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 34460179 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study 32968290 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-medication practices
Number of subjects: 426
Study 35020795 — intervention group
Group type: EXPERIMENTAL
Intervention: FA-modified dairy diet
Number of subjects: 52
Study 35020795 — intervention group
Group type: COMPARATOR
Intervention: Conventional dairy diet
Number of subjects: 52
Study 33471104 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention (EIM) plus usual care
Number of subjects: 198
Study 33471104 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 198
Study 35815801 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 0
Study 35815801 — intervention group
Group type: COMPARATOR
Intervention: Alectinib
Number of subjects: 0
Study 33545940 — intervention group
Group type: EXPERIMENTAL
Intervention: Healing Touch (HT)
Number of subjects: 60
Study 33545940 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 34907064 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and cognitive behavioural therapy (CBT) for 9 weeks each
Number of subjects: 60
Study 34907064 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 60
Study 33566093 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-oriented view (POV)
Number of subjects: 0
Study 33566093 — intervention group
Group type: COMPARATOR
Intervention: Standard view (SV)
Number of subjects: 0
Study 32912514 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 3876
Study 32912514 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3876
Study 35817742 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive nomogram for survival in ICU patients receiving mechanical ventilation
Number of subjects: 16775
Study 34657055 — intervention group
Group type: EXPERIMENTAL
Intervention: Regorafenib (Rego) 160 mg/kg body weight orally every 28 days for 21 days
Number of subjects: 8
Study 34657055 — intervention group
Group type: COMPARATOR
Intervention: S-1 plus Bevacizumab (SB), S-1 orally every 42 days for 28 days and Bev 5 mg/kg intravenously on days 1, 15, and 29
Number of subjects: 8
Study 33369354 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused ultrasound subthalamotomy (active treatment)
Number of subjects: 40
Study 33369354 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 40
Study 32691610 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural assessment tools (specifically the Dementia Observation System (DOS) and Cohen-Mansfield Agitation Inventory (CMAI))
Number of subjects: 103
Study 32389574 — intervention group
Group type: EXPERIMENTAL
Intervention: JR-051
Number of subjects: 0
Study 34924287 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa supplementation (two boluses of triptorelin 0.1 mg)
Number of subjects: 287
Study 34924287 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard HRT-FET protocol only)
Number of subjects: 287
Study 32598098 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% sodium ascorbate
Number of subjects: 110
Study 32598098 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% grape seed extract
Number of subjects: 110
Study 32598098 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% green tea extract
Number of subjects: 110
Study 32598098 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% alpha‐lipoic acid
Number of subjects: 110
Study 32598098 — intervention group
Group type: COMPARATOR
Intervention: No antioxidant (positive control)
Number of subjects: 110
Study 32598098 — intervention group
Group type: COMPARATOR
Intervention: 40% hydrogen peroxide (bleaching agent)
Number of subjects: 110
Study 32598098 — intervention group
Group type: COMPARATOR
Intervention: 35% carbamide peroxide (bleaching agent)
Number of subjects: 110
Study 32598098 — intervention group
Group type: COMPARATOR
Intervention: No bleaching-no antioxidant (negative control, group A)
Number of subjects: 110
Study 32210461 — intervention group
Group type: EXPERIMENTAL
Intervention: Insect-based feed (IBF)
Number of subjects: 957
Study 35315627 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative cognitive therapy combined with rehabilitation exercise
Number of subjects: 86
Study 35315627 — intervention group
Group type: COMPARATOR
Intervention: Standardized health care service (control group)
Number of subjects: 86
Study 34201981 — intervention group
Group type: EXPERIMENTAL
Intervention: Custom-made foot orthotics (n = 53)
Number of subjects: 101
Study 34201981 — intervention group
Group type: COMPARATOR
Intervention: Non-biomechanical effect orthoses (Control group, n = 48)
Number of subjects: 101
Study 34321436 — intervention group
Group type: EXPERIMENTAL
Intervention: RENEwS (emotion regulation intervention)
Number of subjects: 30
Study 34321436 — intervention group
Group type: COMPARATOR
Intervention: Attention control (phone-based)
Number of subjects: 30
Study 33793078 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat consumption (80 g oats containing 3 g beta-glucan daily for 45 days)
Number of subjects: 62
Study 33793078 — intervention group
Group type: COMPARATOR
Intervention: Rice consumption (control group)
Number of subjects: 62
Study 36251392 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bonding (DB) with two-step adhesive
Number of subjects: 100
Study 36251392 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct bonding (DB) with one-step adhesive
Number of subjects: 100
Study 36251392 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect bonding (IDB) with two-step adhesive
Number of subjects: 100
Study 36251392 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect bonding (IDB) with one-step adhesive
Number of subjects: 100
Study 36251392 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 100
Study 34801006 — intervention group
Group type: EXPERIMENTAL
Intervention: App-based intervention including unintentional injury prevention
Number of subjects: 3508
Study 34801006 — intervention group
Group type: COMPARATOR
Intervention: Routine school-based education plus app-based parenting education excluding unintentional injury prevention
Number of subjects: 3508
Study 34815362 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual chlamydia testing through general practice
Number of subjects: 0
Study 34815362 — intervention group
Group type: EXPERIMENTAL
Intervention: Doubling the retesting rate within 4 months of treatment
Number of subjects: 0
Study 34815362 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing partner treatment rate from 30% to 50%
Number of subjects: 0
Study 32272288 — intervention group
Group type: EXPERIMENTAL
Intervention: saMS CBT
Number of subjects: 94
Study 32272288 — intervention group
Group type: COMPARATOR
Intervention: SL
Number of subjects: 94
Study 36180944 — intervention group
Group type: COMPARATOR
Intervention: Best established treatment only (BET)
Number of subjects: 0
Study 34588268 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniocentesis-based predictor models
Number of subjects: 340
Study 34588268 — intervention group
Group type: COMPARATOR
Intervention: Standard institutional protocols (Control)
Number of subjects: 340
Study 32752904 — intervention group
Group type: EXPERIMENTAL
Intervention: GLA‐SE‐Schedule 1
Number of subjects: 23
Study 32752904 — intervention group
Group type: COMPARATOR
Intervention: SE‐Schedule 2
Number of subjects: 23
Study 34838115 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced screening program for early detection of lung, liver, anal, cervical, breast, prostate, colorectal, and skin cancer.
Number of subjects: 0
Study 34838115 — intervention group
Group type: COMPARATOR
Intervention: Standard of care screening according to European AIDS Clinical Society recommendations.
Number of subjects: 0
Study 34838115 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced screening program for early detection of cancer.
Number of subjects: 0
Study 33761679 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanreqing injection combined with azithromycin
Number of subjects: 0
Study 33761679 — intervention group
Group type: COMPARATOR
Intervention: Azithromycin
Number of subjects: 0
Study 33415857 — intervention group
Group type: EXPERIMENTAL
Intervention: Liyan Tongqiao acupuncture
Number of subjects: 60
Study 33415857 — intervention group
Group type: COMPARATOR
Intervention: Neurology treatment
Number of subjects: 60
Study 35617104 — intervention group
Group type: EXPERIMENTAL
Intervention: Treosulfan (30 g/m2 IV)
Number of subjects: 570
Study 35617104 — intervention group
Group type: COMPARATOR
Intervention: Busulfan (6.4 mg/kg IV)
Number of subjects: 570
Study 34145306 — intervention group
Group type: EXPERIMENTAL
Intervention: Uridine + pyruvate supplementation (Uripyr)
Number of subjects: 55
Study 34145306 — intervention group
Group type: COMPARATOR
Intervention: Control group (mitotoxic antibiotic without supplementation)
Number of subjects: 55
Study 32195962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer-based cognitive training program (30 minutes per session, twice a week for 12 weeks)
Number of subjects: 38
Study 32195962 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet computer-based cognitive training program
Number of subjects: 38
Study 32195962 — intervention group
Group type: COMPARATOR
Intervention: Traditional rehabilitation program (control)
Number of subjects: 38
Study 35462581 — intervention group
Group type: EXPERIMENTAL
Intervention: Double faced transverse preputial onlay island flap (group A)
Number of subjects: 68
Study 35462581 — intervention group
Group type: COMPARATOR
Intervention: Transverse inner preputial flap (control group, group B)
Number of subjects: 68
Study 34107730 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 49
Study 34107730 — intervention group
Group type: COMPARATOR
Intervention: Sham procedure (control)
Number of subjects: 49
Study 32539832 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagliptin
Number of subjects: 307
Study 32539832 — intervention group
Group type: COMPARATOR
Intervention: Sitagliptin
Number of subjects: 307
Study 35767175 — intervention group
Group type: EXPERIMENTAL
Intervention: CoolSense
Number of subjects: 140
Study 35767175 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 140
Study 33909260 — intervention group
Group type: EXPERIMENTAL
Intervention: Shuanghuanglian (SHL) treatment (14-day treatment)
Number of subjects: 176
Study 33909260 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose Shuanghuanglian (SHL) treatment
Number of subjects: 176
Study 33909260 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy alone
Number of subjects: 176
Study 35687528 — intervention group
Group type: EXPERIMENTAL
Intervention: delamanid
Number of subjects: 0
Study 35687528 — intervention group
Group type: EXPERIMENTAL
Intervention: bedaquiline
Number of subjects: 0
Study 35687528 — intervention group
Group type: EXPERIMENTAL
Intervention: delamanid+bedaquiline
Number of subjects: 0
Study 34393131 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% propolis
Number of subjects: 60
Study 34393131 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2)
Number of subjects: 60
Study 34393131 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% Glycyrrhiza glabra
Number of subjects: 60
Study 33011482 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (hyperglycemia + normal WBC)
Number of subjects: 4181
Study 33011482 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C (normal glucose + high WBC)
Number of subjects: 4181
Study 33011482 — intervention group
Group type: EXPERIMENTAL
Intervention: Group D (hyperglycemia + high WBC)
Number of subjects: 4181
Study 33011482 — intervention group
Group type: COMPARATOR
Intervention: Group A (normal glucose + normal WBC)
Number of subjects: 4181
Study 35524205 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemotherapy (IO-CT)
Number of subjects: 204
Study 35524205 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab plus chemoradiation (IO-CRT)
Number of subjects: 204
Study 35524205 — intervention group
Group type: COMPARATOR
Intervention: Chemoradiation (CRT)
Number of subjects: 204
Study 33219852 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 162
Study 33219852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 34649284 — intervention group
Group type: EXPERIMENTAL
Intervention: E2 (exogenous estrogen)
Number of subjects: 131
Study 34649284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 34537440 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib 180 mg once daily (7-day lead-in at 90 mg once daily)
Number of subjects: 275
Study 34537440 — intervention group
Group type: COMPARATOR
Intervention: Crizotinib 250 mg twice daily
Number of subjects: 275
Study 34537440 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib
Number of subjects: 275
Study 34537440 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib in patients with baseline brain metastases
Number of subjects: 275
Study 34537440 — intervention group
Group type: EXPERIMENTAL
Intervention: Brigatinib and Crizotinib
Number of subjects: 275
Study 35591811 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional moderate-intensity exercise (TRAD)
Number of subjects: 18
Study 35591811 — intervention group
Group type: EXPERIMENTAL
Intervention: Stair climbing-based high-intensity interval exercise (STAIR)
Number of subjects: 18
Study 33766695 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured hypertension education program (once weekly education session for 4 weeks, home blood pressure monitoring, dose changes in antihypertensives)
Number of subjects: 132
Study 33766695 — intervention group
Group type: COMPARATOR
Intervention: Control group (routine care)
Number of subjects: 132
Study 33766695 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured hypertension education program
Number of subjects: 132
Study 35113805 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD4017 (400 mg oral, bi-daily for 35 days)
Number of subjects: 28
Study 35113805 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 33152538 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent systemic antibiotics at catheter insertion
Number of subjects: 10269
Study 33152538 — intervention group
Group type: COMPARATOR
Intervention: No antibiotics at catheter insertion
Number of subjects: 10269
Study 32021141 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced external counterpulsation (EECP)
Number of subjects: 72
Study 32021141 — intervention group
Group type: COMPARATOR
Intervention: Non‐EECP
Number of subjects: 72
Study 36105248 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithrombotic elastic socks combined with pneumatic treatment intervention
Number of subjects: 60
Study 32300579 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ACBMNC infusion (5 × 10^7 cells/kg)
Number of subjects: 200
Study 32300579 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 200
Study 33769445 — intervention group
Group type: COMPARATOR
Intervention: No comedonecrosis (n = 76)
Number of subjects: 129
Study 33769445 — intervention group
Group type: EXPERIMENTAL
Intervention: Comedonecrosis present
Number of subjects: 129
Study 33769445 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger calcification span
Number of subjects: 129
Study 33220488 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Implementation (BI; a large group didactic learning collaboratives)
Number of subjects: 186
Study 33220488 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation (EI; participatory small group learning collaboratives; enhanced consultation for site champions)
Number of subjects: 186
Study 32500201 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine
Number of subjects: 37
Study 32500201 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 37
Study 34077911 — intervention group
Group type: EXPERIMENTAL
Intervention: Informational intervention (monthly newsletters about park-based PA opportunities, park program brochures, trail maps, and activity guides)
Number of subjects: 171
Study 34077911 — intervention group
Group type: COMPARATOR
Intervention: No intervention (comparison group)
Number of subjects: 171
Study 36530477 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigeminal ganglion block (2% lidocaine 0.5 mL)
Number of subjects: 82
Study 36530477 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control group, C group, n=41)
Number of subjects: 82
Study 32730948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1.5 mA, 15 min)
Number of subjects: 29
Study 32730948 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study 32730948 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 29
Study 35499362 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Epilobium fleischeri extract (twice daily for 4 weeks)
Number of subjects: 23
Study 35499362 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 23
Study 32758405 — intervention group
Group type: COMPARATOR
Intervention: Community sample (unaffected by epilepsy)
Number of subjects: 626
Study 32758405 — intervention group
Group type: COMPARATOR
Intervention: Community sample (suspected epilepsy, did not seek care)
Number of subjects: 626
Study 32758405 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based sample (PWE and caregivers)
Number of subjects: 626
Study 32758405 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher educational attainment and income
Number of subjects: 626
Study 32758405 — intervention group
Group type: EXPERIMENTAL
Intervention: Age, education, income, area of residence, presence of seizure symptoms
Number of subjects: 626
Study 32758405 — intervention group
Group type: COMPARATOR
Intervention: Community participants screening negative for seizures
Number of subjects: 626
Study 32758405 — intervention group
Group type: EXPERIMENTAL
Intervention: Endorsement of treatment methods
Number of subjects: 626
Study 35996845 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n=12) participated in a 10-week supervised progressive walking program
Number of subjects: 24
Study 35996845 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=12) maintained regular habits
Number of subjects: 24
Study 33957621 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride 5 mg twice daily
Number of subjects: 12
Study 33957621 — intervention group
Group type: COMPARATOR
Intervention: Triamterene 50 mg twice daily
Number of subjects: 12
Study 32245480 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM plus Liu Zi Jue (LZJ) exercises
Number of subjects: 354
Study 32245480 — intervention group
Group type: EXPERIMENTAL
Intervention: CHM plus rehabilitation education
Number of subjects: 354
Study 32245480 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus rehabilitation education
Number of subjects: 354
Study 35187621 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ghrelin (0.5 µg/kg/h)
Number of subjects: 73
Study 35187621 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ghrelin (0.25 µg/kg/h)
Number of subjects: 73
Study 35187621 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (both doses)
Number of subjects: 73
Study 35187621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study 33485734 — intervention group
Group type: EXPERIMENTAL
Intervention: Fitness Age
Number of subjects: 180
Study 33485734 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Age
Number of subjects: 180
Study 33485734 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage risk
Number of subjects: 180
Study 33485734 — intervention group
Group type: EXPERIMENTAL
Intervention: High risk results
Number of subjects: 180
Study 33485734 — intervention group
Group type: EXPERIMENTAL
Intervention: Low risk results
Number of subjects: 180
Study 32153120 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary protein pattern 2 (rich in fish and poultry)
Number of subjects: 788
Study 32153120 — intervention group
Group type: COMPARATOR
Intervention: Dietary protein patterns 1 and 3
Number of subjects: 788
Study 36478501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg/day, escalated to a maximum of 400 mg/day)
Number of subjects: 252
Study 36478501 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 36478501 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol (open-label period)
Number of subjects: 252
Study 36478501 — intervention group
Group type: COMPARATOR
Intervention: Placebo (double-blind period)
Number of subjects: 252
Study 34620310 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified Diabetes Nutrition Education (SDNE) for 12 weeks
Number of subjects: 208
Study 34620310 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 208
Study 32473654 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratching (ES) in the luteal phase prior to embryo transfer
Number of subjects: 0
Study 32473654 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0
Study 37084125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight glycemic control (80–110 mg/dL)
Number of subjects: 128
Study 37084125 — intervention group
Group type: COMPARATOR
Intervention: Moderate glycemic control (110–140 mg/dL)
Number of subjects: 128
Study 32735809 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol (IPA) wipe
Number of subjects: 180
Study 32735809 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol (IPA) cap
Number of subjects: 180
Study 32735809 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% chlorhexidine gluconate in 70% IPA wipe
Number of subjects: 180
Study 32769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mayo Scissor technique
Number of subjects: 318
Study 32769657 — intervention group
Group type: COMPARATOR
Intervention: Babcock clamp technique
Number of subjects: 318
Study 32769657 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 318